55687-31-5

Basic information

• Product Name: 1,4-Dihydro-6-(trifluoromethyl)quinoxaline-2,3-dione
• Synonyms: 1,4-Dihydro-6-(trifluoromethyl)quinoxaline-2,3-dione;Lilly-72525;6-TrifluoroMethyl-1,4-dihydroquinoxaline-2,3-dione
• CAS NO: 55687-31-5
• Molecular Formula: C9H5F3N2O2
• Molecular Weight: 230.1434
• Mol File: 55687-31-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 448.6°Cat760mmHg
• Flash Point: 225.1°C
• Appearance: /
• Density: 1.486g/cm³
• Vapor Pressure: 1.16E-08mmHg at 25°C
• Refractive Index: 1.502
• PKA: 9.72±0.20(Predicted)
• CAS DataBase Reference: 1,4-Dihydro-6-(trifluoromethyl)quinoxaline-2,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Dihydro-6-(trifluoromethyl)quinoxaline-2,3-dione(55687-31-5)
• EPA Substance Registry System: 1,4-Dihydro-6-(trifluoromethyl)quinoxaline-2,3-dione(55687-31-5)

Safety Data

• Hazardous Substances Data: 55687-31-5(Hazardous Substances Data)

Usage

Type of compound

Heterocyclic compound

Structure

Contains a quinoxaline ring with a trifluoromethyl group attached to the 6th position

Functional group

1,4-dihydro-2,3-dione

Pharmaceutical industry use

Synthesis of potential drug candidates

Biological activities

Antitumor and anti-inflammatory properties

Organic synthesis use

Building block for the preparation of various heterocyclic compounds

Potential applications

Medicinal and agricultural research and development

InChI:InChI=1/C9H5F3N2O2/c10-9(11,12)4-1-2-5-6(3-4)14-8(16)7(15)13-5/h1-3H,(H,13,15)(H,14,16)

Upstream product

• 95-92-1 oxalic acid diethyl ester 
• 400-98-6 4-trifluoromethyl-2-nitroaniline 
• 368-71-8 4-(trifluoromethyl)-1,2-phenylenediamine 
• 18370-95-1 methyl 2,2,2-trimethoxyacetate 
• 121-17-5 2-chloro-3-nitro-5-trifluoromethylbenzene 
• 54166-79-9 2'-Nitro-4'-(trifluoromethyl)oxanilic acid ethyl ester 
• 144-62-7 oxalic acid 

Downstream Products

• 55686-95-8 6-(trifluoromethyl)-2,3-dichloroquinoxaline 
• 55686-97-0 6-(trifluoromethyl)-3-(phenylthio)-2-chloroquinoxaline 
• 1261078-48-1 (2E,2'E)-diethyl 3,3'-(((6-(trifluoromethyl)quinoxaline-2,3-diyl)bis(azanediyl))bis(4,1-phenylene))diacrylate 
• 1310877-48-5 (2E,2'E)-3,3'-(((6-(trifluoromethyl)quinoxaline-2,3-diyl)bis-(azanediyl))bis(4,1-phenylene))diacrylic acid 

Relevant articles and documents

A One-pot Facile Synthesis of 2,3-Dihydroxyquinoxaline and 2,3-Dichloroquinoxaline Derivatives Using Silica Gel as an Efficient Catalyst

An efficient one-pot reaction has been developed for the synthesis of 2,3-dichloroquinoxaline derivatives 3a–n. The reaction was performed in two steps via a silica gel catalyzed tandem process from o-phenylenediamine and oxalic acid, followed by addition of phosphorus oxychloride (POCl3). A variety of 2,3-dichloroquinoxalines have been obtained in good to excellent overall yields. Eight known compounds 3a–3h were characterized by IR, 1H-NMR, and mass spectroscopies. Compounds 3i–3n without spectroscopic data were characterized by IR, 1H-NMR, 13C-NMR, and mass spectroscopies.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY

The present invention relates to certain certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the "Fused Tricyclic Compounds"), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.